OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Delayed Deutsche Boerse AG 14:11:18 2024-05-29 EDT | ||
| 6.05 EUR | +1.68% |
|
| Current month | -4.95% | ||
| 1 month | -7.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 6.05 | +1.68% |
| 24-05-28 | 5.95 | +0.51% |
| 24-05-27 | 5.92 | +2.42% |
| 24-05-24 | 5.78 | -0.34% |
| 24-05-23 | 5.8 | -2.03% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 02:11 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU01F9 |
| ISIN | DE000SU01F99 |
| Date issued | 2023-10-23 |
| Strike | 1,366 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.71 € |
|---|---|
| Lowest since issue | 5.68 € |
| Spread | 0.07 € |
| Spread % | 1.14% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
